Étude clinique, pharmacocinétique et thérapeutique de l'amikacine en dose unique journalière et en association chez l'enfant neutropénique fébrile

Bertrand, Y; Breant, V.; Vray, C; Nakache, C; Barbe, G; Dürr, F.; Aulagner, G.

doi:10.1016/0929-693x(96)87572-5

Cited by 3 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, such studies reported clinical outcomes similar to or better than those after administration of multiple daily doses of aminoglycoside. [15][16][17][18][19][20][21][22][23][24][25][26][27] An initial dose of gentamicin or tobramycin 7-8 mg/kg every 24 hours has been recommended for children with diseases other than cystic fibrosis. 2 Previous studies of administration of aminoglycosides both every 8 and every 24 hours in oncology patients confirm the high Vd and k el values and large interpatient variability observed in our study (Table 6).…”

Section: Discussionmentioning

confidence: 99%

Tobramycin Pharmacokinetics in Children with Febrile Neutropenia Undergoing Stem Cell Transplantation: Once‐Daily versus Thrice‐Daily Administration

Dupuis¹,

Sung²,

Taylor³

et al. 2004

Pharmacotherapy

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Tobramycin Pharmacokinetics in Children with Febrile Neutropenia Undergoing Stem Cell Transplantation: Once‐Daily versus Thrice‐Daily Administration

Dupuis¹,

Sung²,

Taylor³

et al. 2004

Pharmacotherapy

View full text Add to dashboard Cite

show abstract

Relative pharmacokinetics of three amikacin brands in onco-hemotologic pediatric patients experiencing febrile neutropeina

Jamshaid

Yousuf

Bukhari

et al. 2003

Eur. J. Drug Metab. Pharmacokinet.

View full text Add to dashboard Cite

Three commercially available brands of amikacin were investigated in a parallel study design for the assessment of comparative pharmacokinetics in pediatric oncology patients with chemotherapy-induced neutropenic febrile episode. Amikacin concentration in serum samples was determined by fluorescence polarization immunoassay method using Abbott TDx system. Computer software, PK II was used for computation of pharmacokinetic parameters of amikacin. The serum concentration of all brands nonsignificantly (p > 0.05) varied at all time points, except at 1 and 2 hrs post dosing. At 1 hr post dosing, the serum concentration of brand II varied from rest of two brands. Whereas at 2 hr following I/V infusion, brands II and I were statistically different. Highest serum concentration of 38.69 +/- 1.45 microg/ml was observed in case of brand III while brands I and II showed lower but not significantly different serum concentration values, i.e., 36.30 +/- 1.65 and 37.89 +/- 1.32 microg/ml, respectively when compared with brand I. The other pharmacokinetic parameters of 3 brands found to have non-significant difference (P < 0.05) except, t(1/2)alpha and Cl of brands I and II that deviated statistically significant (p < 0.01). The relative bioavailability of brand II and III as compared with brand I, considered as standard 86.17 and 96.86%, respectively falls within the accepted limits of +/- 20% required for the bioequivalence of any two brands. Based upon findings of the present study, all these brands may be used interchangeably in oncology patients. Further studies, however are needed to determine whether the statistically elevated Cl value in brand II is of any clinical significance.

show abstract

Valeurs de référence des concentrations de médicaments dans les liquides biologiques chez l’enfant

Bédry

Gromb-Monnoyeur

2014

Toxicologie Analytique et Clinique

View full text Add to dashboard Cite

Étude clinique, pharmacocinétique et thérapeutique de l'amikacine en dose unique journalière et en association chez l'enfant neutropénique fébrile

Cited by 3 publications

References 23 publications

Tobramycin Pharmacokinetics in Children with Febrile Neutropenia Undergoing Stem Cell Transplantation: Once‐Daily versus Thrice‐Daily Administration

Tobramycin Pharmacokinetics in Children with Febrile Neutropenia Undergoing Stem Cell Transplantation: Once‐Daily versus Thrice‐Daily Administration

Relative pharmacokinetics of three amikacin brands in onco-hemotologic pediatric patients experiencing febrile neutropeina

Valeurs de référence des concentrations de médicaments dans les liquides biologiques chez l’enfant

Contact Info

Product

Resources

About